 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...234567891011121314 |
- |||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, bamlanivimab/etesevimab (LY-CoV555/LY-CoV016) / Eli Lilly
Enrollment open, Combination therapy: BLAZE-2: A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (clinicaltrials.gov) - Aug 11, 2020
P3, N=2400, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting
- || bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Enrollment closed: A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 (clinicaltrials.gov) - Aug 7, 2020
P1, N=40, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, bamlanivimab/etesevimab (LY-CoV555/LY-CoV016) / Eli Lilly
New P3 trial, Combination therapy: BLAZE-2: A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (clinicaltrials.gov) - Aug 6, 2020
P3, N=2400, Not yet recruiting, Sponsor: Eli Lilly and Company
- | bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
New P3 trial: TICO: ACTIV-3: Therapeutics for Inpatients With COVID-19 (clinicaltrials.gov) - Aug 6, 2020
P3, N=10000, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- |||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, bamlanivimab/etesevimab (LY-CoV555/LY-CoV016) / Eli Lilly, etesevimab (JS016) / Chinese Academy of Sciences, Shanghai Junshi Biosci, Eli Lilly
Enrollment open: BLAZE-1: A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (clinicaltrials.gov) - Jun 16, 2020
P2, N=400, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases, bamlanivimab/etesevimab (LY-CoV555/LY-CoV016) / Eli Lilly, etesevimab (JS016) / Chinese Academy of Sciences, Shanghai Junshi Biosci, Eli Lilly
New P2 trial: BLAZE-1: A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (clinicaltrials.gov) - Jun 11, 2020
P2, N=400, Not yet recruiting, Sponsor: Eli Lilly and Company
- || LY-CoV555 / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
شركة ليلي @LillyPad تعلن أنها ستتقدم بدمج مشروعيها العلاجيين في كوكتيل الاجسام المضادة الذي يحتوي على 💉 JS016 و 💉 LY-CoV555 بالإضافة إلى أجسام مضادة أخرى تستهدف نقاط متعددة من الفيروس لعلاج كوفيد-١٩ ⚠️بهذه الطريقة العلاجية تم التغلب على الايبولا https://t.co/UQi6XOjBRs (147) (Twitter) - Jun 8, 2020
- || bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
New P1 trial: A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 (clinicaltrials.gov) - Jun 1, 2020
P1, N=40, Recruiting, Sponsor: Eli Lilly and Company
- |||| Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
"There was no hype when Anthony S. Fauci of the National Institute of Allergy and Infectious Diseases relayed the outcomes of a study on a potential treatment for covid-19 on Wednesday... 1/2 https://t.co/9wg11xPnbx (Twitter) - May 1, 2020
- |||| remdesivir (GS-5734) / Gilead, Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
@GileadSciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral #Remdesivir for #COVID19, which was tested @providence. @ODayMD @WalterUrba https://t.co/E5SBWUTTNt (Twitter) - Apr 30, 2020
- |||| remdesivir (GS-5734) / Gilead, Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19 https://t.co/0vxo1NogNB (Twitter) - Apr 29, 2020
- ||||| remdesivir (GS-5734) / Gilead, Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
Clinical: .@NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced #COVID19 | NIH: National Institute of Allergy and Infectious Diseases https://t.co/2ijaP0bHCE (Twitter) - Apr 29, 2020
- ||||| remdesivir (GS-5734) / Gilead, Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
Clinical: Looking forward to seeing the data in the NIH Clinical Trial, which has been reported to Show Remdesivir Accelerates Recovery from Advanced COVID-19 | NIH: National Institute of Allergy and Infectious Diseases https://t.co/ls6d4uMOiH (Twitter) - Apr 29, 2020
- ||||| remdesivir (GS-5734) / Gilead, Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
Clinical: NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 | NIH: National Institute of Allergy and Infectious Diseases https://t.co/0HJLuZ8z6k (Twitter) - Apr 29, 2020
- ||||| remdesivir (GS-5734) / Gilead, Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
Clinical: The official press release. Congrats @NerdmannID @goepfert_paul @AlisaPeinhardt for leading this work @uabmedicine NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 | NIH: National Institute of Allergy and Infectious Diseases https://t.co/6atP3jIvFY (Twitter) - Apr 29, 2020
- ||||| remdesivir (GS-5734) / Gilead, Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
Clinical: NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 | NIH: National Institute of Allergy and Infectious Diseases https://t.co/fx85r1ShQa (Twitter) - Apr 29, 2020
- |||| remdesivir (GS-5734) / Gilead, Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19 https://t.co/74LZ671AAe (Twitter) - Apr 29, 2020
- |||| remdesivir (GS-5734) / Gilead, Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
@GileadSciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral #Remdesivir for #Covid_19 https://t.co/3lvmX83bwa (Twitter) - Apr 29, 2020
- ||||| remdesivir (GS-5734) / Gilead, Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
Gilead is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational antiviral #remdesivir for the treatment of COVID-19. We understand that the trial has met its primary endpoint https://t.co/1nO7eYBzBm (Twitter) - Apr 29, 2020
- ||| Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
⚠️Another hotspot: "Detroit is starting to show some signs that they're going to take off," says Dr Fauci, director of the National Institute of Allergy and Infectious Diseases on @GMA. #COVID19 (Twitter) - Mar 30, 2020
- |||| Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
#Truth "immutable" Truth everlasting @8Blums @IStedman @kinsellawarren @CathyEngMD #ScienceMatters #COVID19 Anthony S. Fauci, M.D., NIAID Director | NIH: National Institute of Allergy and Infectious Diseases https://t.co/1J5wypjH5m (Twitter) - Mar 22, 2020
- ||||| Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
Clinical: NIH Clinical Trial of Investigational Vaccine for COVID-19 Begins | NIH: National Institute of Allergy and Infectious Diseases https://t.co/LHOG8pexZH (Twitter) - Mar 16, 2020
- ||||| Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases, Coronavirus Vaccine / University of Texas, National Institute of Allergy and Infectious Diseases
Clinical: NIH Clinical Trial of Investigational Vaccine for COVID-19 Begins | NIH: National Institute of Allergy and Infectious Diseases https://t.co/BGSMbsE4vD. Today the first volunteer received a #COVID19 vaccine as part of a Phase I trial. This is GEAT NEWS! (Twitter) - Mar 16, 2020
- ||| Coronavirus (2019-nCoV) antibody therapy / AbCellera, National Institute of Allergy and Infectious Diseases
Covid-19, accordo tra AbCellera e Lilly per sviluppare anticorpi terapeutici https://t.co/z2AZ9S9ngu di @AboutPharmaHPS (Twitter) - Mar 16, 2020